The Juno/Wuxi venture will soon become one of just a few Chinese cell therapy players with a stock exchange listing.
Shortly after canning its lead and acquiring the NK cell company Cytosen, Kiadis flips part of the tech to Sanofi.
Two progressive multiple sclerosis subjects in a high-dose six-patient cohort given ATA188 have seen their disease reverse.
A week after one Bristol-Myers Squibb approval decision was delayed a second suffers a similar fate, and the group’s CVR slowly unravels.
The Chinese group sees responses in all five subjects treated with its allogeneic anti-CD7 Car-T therapy.